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1. Resurgence
Bacteriophages are generally considered to be the most prevalent biological
entities on planet Earth [1], with astronomical estimates of their myriad abundance.
These fascinatingly diverse viruses, which infect bacterial cells, were discovered in
the second decade of the twentieth century. Under the light microscope, bacterial
cells were seen to be apparently eaten away, hence the scientific Greek naming of
these viruses meaning literally “bacteria eaters”. The middle decades of that century
gave us a first glimpse of these viral particles, via their imaging using the technique
of negative stain electron microscopy. The morphology of the first studied particles
was symbolic of the so-called Space Age in which these discoveries took place:
The archetypal Phi X 174 evoked the first artificial satellites, while the T-even
phages resembled prototypic lunar landing vehicles.
Such latter-day futuristic symbolismmay seem amusingly outdated by the time of
writing. However, the undoubtedly ancient bacteriophages are now riding a new
wave of technological advancement: synthetic biology. Interestingly, this returns us to
the potential revolution in healthcare that surrounded the initial discovery of bacte-
riophages. The simple fact is that phages, which is a common abbreviation used when
referring to these viruses, are capable of selective killing of bacterial cells of a given
species or strain. In other words, phages are exquisitely specific microbial control
agents. In the current antimicrobial resistance era [2], exemplified by the ESKAPE
organisms, which is to name only the vanguard of untreatable pathogenic microbes,
phages offer a potential panacea for the treatment of pathogenic bacterial infection.
Indeed, deployment of phages to treat bacterial infections in animals and
humans was the first exploitative use of these virus entities. Their promise as
therapeutic agents was, nevertheless, soon eclipsed by the rise of antibiotics. How-
ever, partly by economic necessity, the refinement of such phage-mediated treat-
ments persisted in the former USSR [3]. Today, the fruit of that legacy provides
effective alternative treatment in an era of antibiotic-resistant microorganisms [4].
Including the long-standing cases of treatment achieved within the pioneering
hospitals in the former Soviet territory of Georgia [5], there have also been recent
high-profile cases [6], as well as a rise in commercial offerings based upon sound
scientific discovery [7].
2. Repurposed
In a commercial sense, phages are regarded as cheap to manufacture, because
they will naturally multiply within their target bacteria. However, process control at
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industrial scales presents challenges: most notably in efficiency and reproducibility
but also via complications in terms of sterility and purity [7, 8]. Knowing how to
keep prevalent diverse phage types out of a production facility will doubtless be as
important as manufacturing commercially relevant types efficiently. When consid-
ering efficiency of phage production, the ultimate cost depends upon the measures
that have to be taken, from plant and tooling to culture volume and starter culture
characteristics. Investigations of multiplicity of infection, and economics of scale,
plus processing of waste effluent are all factors that will impact costs and afford-
ability [9]. Upscale and purity of phage will have an impact on any type of technol-
ogy or application that is currently envisaged for phage, from antimicrobial therapy
to phage particles as nanomaterials.
We can consider that phage genetic and structural insights are opening doors in
nanotechnology and synthetic biology applications, which have a translation
potential back into healthcare. That medical relevance is not limited to antimicro-
bial applications but also encompasses cancer and gene therapy. Indeed, phage
display technologies are revolutionising the high-resolution visualisation of meta-
static tumours in surgical settings by enabling unambiguous contrast.
Regarding the structure of phage particles, as nanoscale parts assembling into a
mechanised vehicle for DNA packaging and delivery, their production as potential
therapeutic agents might well be due a synthetic makeover. The concept of a phage
cocktail is now very well tested: namely, several phage types recognising the same
bacterial species but attacking that cell type in different ways. Phage cocktails are
known to make it less likely that the targeted cells can survive via adaptation, as is
known to be the case via treatment with a single phage type. Lately, the
reprogramming of a phage DNA payload to ensure target cell death rather than
phage latent persistence in a population of cells has also been found to be effective
[6]. Indeed, such engineering approaches have been used to alter the DNA payload
injected by the phage particle in order to make phages more effective at cell killing,
rather than infection per se [6, 10].
Nevertheless, from an efficiency and medical regulatory perspective, it could be
advantageous to have one or just a few medically approved phage chassis. These
might be envisaged as phages known for their low immunogenicity profiles in
patients. Perhaps these may be patient-specific, in which the therapeutic DNA
payload is installed in a phage chassis matched to the current patient’s immune
tolerance. Then one can envisage a programmable targeting built in via a synthetic
biology approach of re-engineering components of these standardised phages to
recognise any desired bacterial target. Demonstrations of swapping out the
targeting structures (i.e., tails and adsorption features) have been equally impres-
sive in principle [11, 12]. Thus, furthering a detailed knowledge of phage structure
beyond well-studied phage types [13] is incentivised.
3. Reimagined
One of the most fascinating things about phages is that they are hotbeds of
molecular adaptation. An eclectic and presently largely arcane phage-encoded pro-
tein panoply supports the survival and success of the diverse bacteriophage types.
The exploitation of deciphered elements of this phage protein repertoire was central
to development of the recombinant biotechnology revolution. Circuitously, these
very molecular tools are bringing about the technological revolution that promises
to lend a starring role of phage in a biotechnologically repurposed guise. In fact,
looking into that mesmerising pool of proteins of unknown function [14], it is easy
to believe that the phages’ encoded box of tricks isn’t yet done revolutionising
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applied biotechnology. The numbers of completely sequenced diverse phage
genomes expand at a prolific rate, and the mysteries of their encoded protein
manifest may yet take a long time and a lot of care to unravel.
Phage biology then, played a central role in the elucidation of some of the major
genetic insights of the twentieth century. Other ground-breaking studies in that
century concerned phage genome replication, the structures of phage particles and
their assembly, and mechanisms of bacterial cell immunity and its viral subversion.
Modern techniques in genomics, proteomics, and structural biology are adding
novel insights even now [13, 15]. This combination of precision studies illuminates
the plasticity of macromolecular and cellular biology in this perennial cauldron of
evolutionary cat and mouse.
In terms of replicative strategies, phage activity in a cell involves an interesting
sideway taken on biological processes. The enzymatic agents encoded by phages
have applications in laboratory research technologies, applied molecular evolution
techniques, and also novel ways to make DNA for therapeutic and technological use:
free of the heretofore necessity for bacterial cell passage to propagate this DNA and
thus of bacterial propagation sequences, including antibiotic resistance genes. The
insights from phages therefore bring us to the brink of revolutionising applications
as diverse as human gene therapy, cell and regenerative medicine, and DNA as data
storage (Figure 1).
4. Rebooted
Finally, looking beyond what we have discovered and tested, beyond this vol-
ume and into that potential future of synthetically modified bacteriophages with
Figure 1.
Bacteriophages can be envisaged as natural microbial control agents, as well as machines for targeted synthetic
genetic programming. The encoded proteins, as well as the structures of phages, offer a multitude of possibilities
as outlined in this introductory chapter and detailed in the volume.
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diverse uses, what might we find? Perhaps we might find nanomachines inspired in
their design by the multifarious forms and mechanisms of both known and newly
studied types of these viruses, lightning-fast genotyping of bacterial infections at
point of care, and efficiently timely synthetic tooling of medically approved phages
to rapidly quell those infections, even on the scale of a few hours. We might also
find synthetic phages reprogramming the microbiome, both by selective population
control and by targeted and firewalled genetic modification in situ, and even the
possibility of tooling wild species of bacteria for bioremediation purposes via
reversible and firewalled genetic modification. There could be phage-encoded ele-
ments brought together in new and as yet unimagined combinations to effect all
manner of building and alteration performed at the macromolecular scale. The
future is always imagined yet unseen: with phages in mind that refers both to its
dazzling scale of possibility and in its infinitesimal scale of operation. The bacterio-
phages will be just as much a major part of that synthetic future, as they have ever
seemingly been in nature to this day.
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